Kabra Drugs P/E Ratio
Current P/E Ratio
6.09
Low Valuation
Very Low - Potentially undervalued or facing challenges
Kabra Drugs P/E ratio. Kabra Drugs (KABRADG) P/E ratio is 6.09 (Low), EPS (TTM) ₹2.09, current price ₹18.08 on BSE — Very Low - Potentially undervalued or facing challenges. For live price, revenue and the complete fundamental profile, see Kabra Drugs stock price NSE.
Current Valuation Metrics
P/E Ratio
6.09
Current Price
₹18.08
EPS (TTM)
₹2.09
Exchange
BSE
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
56.45
Sector Median
32.5
Sector Rank
#8 of 199
Sector Percentile
4.0%
KABRADG P/E Ratio — Valuation Signal & Historical Context
Kabra Drugs P/E 6.09 — signal: Undervalued. Also explore KABRADG share price data to track price trends across different timeframes.
- Stock appears undervalued with PE of 6.09, suggesting potential buying opportunity
- Trading at discount to sector average PE of 56.45
KABRADG vs Healthcare Peers — P/E Ratio Comparison
Kabra Drugs P/E 6.09 vs Healthcare average 56.45, median 32.5 — range 2.04–740.29.
Sector Average
56.45
Sector Median
32.5
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |
| Shelter Pharma | SHELTER | 6.96 | ₹59 | Low |